Float Short %

21.04

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

0.01

EPS Last/This Y

0.12

EPS This/Next Y

-0.17

Price

1.12

Target Price

9.18

Analyst Recom

1.21

Performance Q

-19.29

Relative Volume

1.29

Beta

0.34

Ticker: ALLO

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	ALLO	1.43	0.24	0.18	6499
2025-04-15	ALLO	1.47	0.24	2.00	6501
2025-04-16	ALLO	1.405	0.25	999.99	6545
2025-04-17	ALLO	1.455	0.26	1.33	6596
2025-04-18	ALLO	1.45	0.26	0.59	6596
2025-04-21	ALLO	1.43	0.25	0.09	5653
2025-04-22	ALLO	1.585	0.24	0.08	5754
2025-04-23	ALLO	1.605	0.24	0.02	5933
2025-04-24	ALLO	1.565	0.22	0.67	6213
2025-04-25	ALLO	1.55	0.22371012209531	0.0076045627376426	6214
2025-04-28	ALLO	1.57	0.21855194929902	1.8571428571429	6345
2025-04-29	ALLO	1.54	0.23	0.03	6417
2025-04-30	ALLO	1.68	0.22	0.00	6682
2025-05-01	ALLO	1.685	0.22	0.00	6707
2025-05-02	ALLO	1.705	0.22	0.45	6704
2025-05-05	ALLO	1.615	0.22	0.32	6717
2025-05-06	ALLO	1.27	0.22	0.32	6749
2025-05-07	ALLO	1.195	0.23	1.76	6802
2025-05-08	ALLO	1.175	0.23	0.10	6857
2025-05-09	ALLO	1.15	0.23	0.01	6864
2025-05-12	ALLO	1.16	0.23	0.38	6924
2025-05-13	ALLO	1.13	0.23	0.07	6982
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	ALLO	1.43	29.0	-	-1.12
2025-04-15	ALLO	1.46	29.0	-	-1.12
2025-04-16	ALLO	1.40	29.0	-	-1.12
2025-04-17	ALLO	1.45	29.0	-	-1.12
2025-04-18	ALLO	1.45	29.0	-	-1.20
2025-04-21	ALLO	1.42	19.1	-	-1.20
2025-04-22	ALLO	1.59	19.1	-	-1.20
2025-04-23	ALLO	1.61	19.1	-	-1.20
2025-04-24	ALLO	1.57	19.1	-	-1.20
2025-04-25	ALLO	1.55	19.1	-	-1.20
2025-04-28	ALLO	1.57	20.0	-	-1.20
2025-04-29	ALLO	1.54	20.0	-	-1.20
2025-04-30	ALLO	1.68	20.0	-	-1.20
2025-05-01	ALLO	1.69	20.0	-	-1.20
2025-05-02	ALLO	1.70	20.0	-	-1.20
2025-05-05	ALLO	1.62	20.0	-	-1.20
2025-05-06	ALLO	1.27	20.0	-	-1.20
2025-05-07	ALLO	1.20	20.0	-	-1.20
2025-05-08	ALLO	1.17	20.0	-	-1.20
2025-05-09	ALLO	1.16	20.0	-	-1.20
2025-05-12	ALLO	1.17	20.0	-	-1.20
2025-05-13	ALLO	1.12	22.4	-	-1.20
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	ALLO	-0.26	-6.02	24.91
2025-04-15	ALLO	-0.26	-6.02	24.91
2025-04-16	ALLO	-0.26	-6.02	24.91
2025-04-17	ALLO	-0.26	-6.02	24.91
2025-04-18	ALLO	-0.26	-6.02	24.91
2025-04-21	ALLO	-0.26	-6.12	24.91
2025-04-22	ALLO	-0.26	-6.12	24.91
2025-04-23	ALLO	-0.27	-6.12	24.43
2025-04-24	ALLO	-0.28	-6.12	24.43
2025-04-25	ALLO	-0.28	-6.12	24.43
2025-04-28	ALLO	-0.28	-10.89	23.06
2025-04-29	ALLO	-0.28	-10.89	23.06
2025-04-30	ALLO	-0.28	-10.89	23.06
2025-05-01	ALLO	-0.28	-10.89	23.06
2025-05-02	ALLO	-0.28	-10.89	23.06
2025-05-05	ALLO	-0.28	-11.07	23.06
2025-05-06	ALLO	-0.28	-11.07	23.06
2025-05-07	ALLO	-0.28	-11.07	22.91
2025-05-08	ALLO	-0.28	-11.07	22.91
2025-05-09	ALLO	-0.28	-11.07	22.91
2025-05-12	ALLO	-0.28	-6.39	21.04
2025-05-13	ALLO	-0.28	-6.39	21.04
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.28

Avg. EPS Est. Current Quarter

-0.28

Avg. EPS Est. Next Quarter

-0.27

Insider Transactions

-0.28

Institutional Transactions

-6.39

Beta

0.34

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-97.9

Target Price

9.18

P/E

Forward P/E

PEG

P/S

12357.08

P/B

0.57

P/Free Cash Flow

EPS

-1.34

Average EPS Est. Cur. Y

-1.2

EPS Next Y. (Est.)

-1.37

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.29

Return on Equity vs Sector %

-84.7

Return on Equity vs Industry %

-67.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.08

EBIT Estimation

Allogene Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 226

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today

news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance

stock history ALLO – Allogene Therapeutics, Inc. invest stock market

stock prices ALLO premarket after hours

ticker ALLO fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALLO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y